FamiCord AG (ETR:V3V)

Germany flag Germany · Delayed Price · Currency is EUR
3.970
+0.050 (1.28%)
May 29, 2026, 5:35 PM CET
Market Cap69.20M +0.3%
Revenue (ttm)87.58M +7.3%
Net Income-5.84M
EPS-0.28
Shares Out 17.43M
PE Ration/a
Forward PE132.33
Dividendn/a
Ex-Dividend Daten/a
Volume701
Open3.970
Previous Close3.920
Day's Range3.970 - 3.970
52-Week Range3.800 - 7.650
Beta0.63
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About FamiCord AG

FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable ... [Read more]

Sector Healthcare
Founded 1997
Employees 766
Stock Exchange Deutsche Börse Xetra
Ticker Symbol V3V
Full Company Profile

Financial Performance

In 2025, FamiCord AG's revenue was 88.17 million, an increase of 7.29% compared to the previous year's 82.18 million. Losses were -6.30 million, -48.06% less than in 2024.

Financial Statements

News

FamiCord AG Quarterly report: Q1 2026

FamiCord AG has published its Q1 2026 quarterly earnings report on May 29, 2026.

2 days ago - Filings

FamiCord AG Earnings release: Q4 2025

FamiCord AG released its Q4 2025 earnings on April 30, 2026, summarizing the period's financial results.

4 weeks ago - Filings

FamiCord AG Annual report: Q4 2025

FamiCord AG has published its Q4 2025 annual report on April 30, 2026.

4 weeks ago - Filings

FamiCord AG Slides: Q4 2025

FamiCord AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 30, 2026.

4 weeks ago - Filings

FamiCord AG Earnings Call Transcript: Q3 2025

Revenue and EBITDA improved year-over-year, driven by recurring payments and new CDMO contracts. Settled Cryo-Save litigation opens new revenue opportunities, while the placenta business in Germany is set to launch in Q3 next year. M&A activity is limited by capital constraints.

6 months ago - Transcripts

FamiCord AG Quarterly report: Q3 2025

FamiCord AG has published its Q3 2025 quarterly earnings report on November 21, 2025.

6 months ago - Filings

FamiCord AG Slides: Q3 2025

FamiCord AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 21, 2025.

6 months ago - Filings

FamiCord AG Transcript: Status Update

Leading European stem cell bank projects strong 2024 growth, with revenue guidance of €85–95 million and EBITDA of €8.7–10.3 million. Market share exceeds 55% in Europe, with expansion focused on new products and geographies. Placenta banking rollout continues, with regulatory delays in Germany but imminent launch in Portugal.

9 months ago - Transcripts

FamiCord AG Earnings Call Transcript: Q2 2025

Stem cell banking penetration in Europe remains low but is recovering, with strong growth in Eastern Europe and new product rollouts like placenta banking. Guidance is realistic, with further EBITDA gains expected from acquisitions and a shift in focus to core operations.

9 months ago - Transcripts

FamiCord AG Quarterly report: Q2 2025

FamiCord AG has published its Q2 2025 quarterly earnings report on August 27, 2025.

9 months ago - Filings